- Home
- ABVC vs TELA Comparison
ABVC vs TELA Comparison
Compare ABVC & TELA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ABVC | TELA |
|---|---|---|
| Founded | 2015 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 50.5M | 50.8M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | ABVC | TELA |
|---|---|---|
| Price | $2.04 | $0.94 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $3.31 |
| AVG Volume (30 Days) | 55.6K | ★ 60.7K |
| Earning Date | 11-03-2025 | 03-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $797,916.00 | ★ $77,055,000.00 |
| Revenue This Year | $735.18 | $18.41 |
| Revenue Next Year | N/A | $15.20 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 56.52 | 12.24 |
| 52 Week Low | $0.40 | $0.86 |
| 52 Week High | $5.48 | $2.96 |
Technical Indicators
Market Signals| Indicator | ABVC | TELA |
|---|---|---|
| Relative Strength Index (RSI) | 40.96 | 35.93 |
| Support Level | $2.00 | $0.93 |
| Resistance Level | $2.20 | $1.03 |
| Average True Range (ATR) | 0.12 | 0.06 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 22.86 | 4.35 |
Price Performance
Historical ComparisonAbout ABVC ABVC BioPharma Inc.
ABVC BioPharma Inc is a clinical-stage biopharmaceuticals company with an active pipeline of six drugs and one medical device (ABV-1701/Vitargus) under development. Its drug products focus on utilizing its licensed technology to conduct proof-of-concept trials through Phase II of the clinical development process. The firm specializes in botanically based solutions that deliver high efficacy with low toxicity for improved health outcomes.
About TELA TELA Bio Inc.
TELA Bio Inc a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. Its growing product portfolio is purposefully designed to leverage the patient's natural healing response while minimizing long-term exposure to permanent synthetic materials. The company's OviTex portfolio consists of multiple product configurations intended to address various surgical procedures within hernia repair and abdominal wall reconstruction, including ventral, inguinal, and hiatal hernia repair.